Table 3.

5 year Relapse-Free Survival and 5 year Overall Survival among patients that received and did not receive bisphosphonates. Estimates are shown for all patients and according to tumor subtype.

	N Patients	Relapse-Free Survival			Overall Survival
		N Events	5-Year Estimates (95% CI)	Log-rank P	N Events	5-Year Estimates (95% CI)	Log-rank P
All patients
No BIS	1410	405	0.71(0.68, 0.73)		352	0.77(0.74, 0.79)
Yes BIS	39	8	0.81(0.64, 0.9)	.28	7	0.83(0.65, 0.92)	.42
Hormone Positive
No BIS	767	171	0.77(0.73, 0.8)		144	0.84(0.81, 0.87)
Yes BIS	24	6	0.77(0.54, 0.9)	.72	5	0.8(0.53, 0.92)	.59
HER2 Positive
No BIS	250	91	0.65(0.59, 0.71)		69	0.78(0.72, 0.83)
Yes BIS	8	1	0.87(0.36, 0.98)	.24	1	0.88(0.39, 0.98)	.43
Triple Negative
No BIS	376	138	0.62(0.57, 0.67)		135	0.61(0.55, 0.66)
Yes BIS	7	1	0.86(0.33, 0.98)	.25	1	0.86(0.33, 0.98)	.30